Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 12Completed 11Active not recruiting 10Withdrawn 4Unknown 4Terminated 2Suspended 1Not yet recruiting 1No longer available 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Extensive Stage Lung Small Cell Cancer 1Carcinoma, Pancreatic Ductal 1Carcinoma 1

Interventions

Dexamethasone 16daratumumab 14Bortezomib 11Lenalidomide 9pomalidomide 7Calcium Dobesilate 6isatuximab 4belantamab mafodotin 4Cyclophosphamide 4carfilzomib 3Melphalan 3tocilizumab 2iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2Biopsy 2zanubrutinib 1trametinib 1talquetamab 1selinexor 1pembrolizumab 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Multiple Myeloma × selinexor × Clear all
NCT07569757 2026-05-08

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
260 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡